

type of report	Current report
number	44/2012
company	PHARMENA

Public offering of series C shares with pre-emptive rights

The Management Board of PHARMENA S.A. informs that pursuant to resolution no. 3 adopted on 21st August 2012 during Extraordinary General Meeting of Pharmena S.A. on the Company's share capital increase through issue of series C bearer shares through private placement with pre-emptive rights for hitherto shareholders and the change to the Company's Articles of Association, the Issuer will commence public offering of series C shares with pre-emptive rights.

The goal of the issue is to obtain funds for further clinical trials on innovative anti-atherosclerosis medicinal product 1-MNA.

At the same time, the Management Board of PHARMENA S.A. informs that pursuant to resolution no. 1 adopted on 21st August 2012 during Extraordinary General Meeting of Pharmena S.A., the Meeting repealed resolution no. 16 adopted on 14th May 2012 during Ordinary General Meeting of Pharmena S.A. on the Company's share capital increase through the issue of series C ordinary bearer shares with no pre-emptive rights. Pursuant to resolution no. 2 adopted on 21st August 2012 during Extraordinary General Meeting of Pharmena S.A., the Meeting repealed resolution no. 17 adopted on 14th May 2012 during Ordinary General Meeting of Pharmena S.A. on the introduction of the Company's shares to organized trading.

The information is made public due to the fact that the goal of public offering of series C shares is to obtain funds for further clinical trials on anti-atherosclerosis medicinal product 1-MNA, which results may have considerable influence on the Issuer's financial and economic situation in the future.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board